Follica sees bushy prospects in baldness therapy

The San Francisco Chronicle takes a hard look at the new baldness therapies in the pipeline, concentrating much of its attention on Follica, which is focusing on microdermabrasion to remove an outer layer of dead cells. That process, encouraged by a new therapy, would allow deeper cells to spur the growth of new hair follicles. "We view it as a very early, very high-risk project," InterWest Partners' Chris Ehrlich tells the newspaper. "But if it works, it would be great."

Insurers have proved reluctant to provide coverage for baldness therapies, but developers are counting on consumers who are passionate about avoiding balding.

- read the article from the San Francisco Chronicle

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.